The utility of BRAF testing in the management of papillary thyroid cancer

Oncologist

Volumn 15, Issue 12, 2010, Pages 1285-1293

  Melck, Adrienne L ^a   Yip, Linwah ^a   Carty, Sally E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF; Molecular diagnostics; Mutational analysis; Papillary thyroid cancer

Indexed keywords

B RAF KINASE;

ALGORITHM; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CARCINOGENESIS; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; GENE IDENTIFICATION; GENETIC CORRELATION; GENETIC VARIABILITY; HUMAN; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

CARCINOMA, PAPILLARY; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 78650982833     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0156     Document Type: Review

References (60)

1. Albores-Saavedra J, Henson DE, Glazer E et al. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: A morphological and epidemiological study. Endocr Pathol 2007;18:1-7.
2. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
3. Nikiforov YE. Thyroid carcinoma: Molecular pathways and therapeutic targets. Mod Pathol 2008;21(suppl 2):S37-S43.
4. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: A meta-analysis. Cancer 2007;110:38-46.
5. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009;19:1351-1361.
6. Lupi C, Giannini R, Ugolini C et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:4085-4090.
7. Yip L, Nikiforova MN, Carty SE et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 2009;146:1215-1223.
8. Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-5404.
9. Chiosea S, Nikiforova M, Zuo H et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol 2009;20:122-126.
10. Hegeds̈ L. Clinical practice: The thyroid nodule. N Engl J Med 2004;351: 1764-1771.
11. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
12. Baloch ZW, LiVolsi VA, Asa SL et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008;36:425-437.
13. Zatelli MC, Trasforini G, Leoni S et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fineneedle aspiration biopsies. Eur J Endocrinol 2009;161:467-473.
14. Jo YS, Huang S, Kim YJ et al. Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf) 2009;70:139-144.
15. Xing M, Tufano RP, Tufaro AP et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: A new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004;89:2867-2872.
16. Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009;94:2092-2098.
17. Cohen Y, Rosenbaum E, Clark DP et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid:Apotential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004;10: 2761-2765.
18. Kumagai A, Namba H, Akanov Z et al. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J 2007;54: 399-405.
19. Xing M, Clark D, Guan H et al. BRAF mutation testing of thyroid fineneedle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 2009;27:2977-2982.
20. Chung KW, Yang SK, Lee GK et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006;65:660-666.
21. Kim SW, Lee JI, Kim JW et al. BRAFV600E mutation analysis in fineneedle aspiration cytology specimens for evaluation of thyroid nodule: A large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab 2010;95:3693-3700.
22. Lee HJ, Choi J, Hwang TS et al. Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system. Am J Clin Pathol 2010;133:802-808.
23. Nikiforov YE, Biddinger PW, and Thompson L. Diagnostic Pathology and Molecular Genetics of the Thyroid, first Edition. Baltimore, MD: Lippincott, Williams and Wilkins, 2009:1-381.
24. Ohori NP, Nikiforova MN, Schoedel KE et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance." Cancer Cytopathol 2010;118:17-23.
25. Jin L, Sebo TJ, Nakamura N et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006;15:136-143.
26. Kebebew E, Weng J, Bauer J et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-470; discussion 470-471.
27. Elisei R, Ugolini C, Viola D et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab 2008;93:3943-3949.
28. Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-762.
29. Elisei R, Molinaro E, Agate L et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010;95:1516-1527.
30. Cushing SL, Palme CE, Audet N et al. Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope 2004;114:2110-2115.
31. Lloyd R, DeLellis R, Heitz P et al. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Endocrine Organs. Lyon, France: IARC Press International Agency for Research on Cancer, 2004:1-320.
32. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract 2007;13:498-512.
33. Besic N, Pilko G, Petric R et al. Papillary thyroid microcarcinoma: Prognostic factors and treatment. J Surg Oncol 2008;97:221-225.
34. Pelizzo MR, Boschin IM, Toniato A et al. Papillary thyroid microcarcinoma (PTMC): Prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol 2006;32:1144-1148.
35. Arora N, Turbendian HK, Kato MA et al. Papillary thyroid carcinoma and microcarcinoma: Is there a need to distinguish the two? Thyroid 2009;19: 473-477.
36. Park YJ, Kim YA, Lee YJ et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clini-copathological features, and immunohistochemical findings. Head Neck 2010;32:38-45.
37. Lee X, Gao M, Ji Y et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009;16:240-245.
38. Kwak JY, Kim EK, Chung W Y et al. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 2009;253:854-860.
39. Rodolico V, Cabibi D, Pizzolanti G et al. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <1 cm and their paired lymph node metastases. Cancer 2007;110:1218-1226.
40. Sakorafas GH, Sampanis D, Safioleas M. Cervical lymph node dissection in papillary thyroid cancer: Current trends, persisting controversies, and unclarified uncertainties. Surg Oncol 2010;19:e57-e70.
41. White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007;31:895-904.
42. Roh JL, Park JY, Kim JM et al. Use of preoperative ultrasonography as guidance for neck dissection in patients with papillary thyroid carcinoma. J Surg Oncol 2009;99:28-31.
43. National Cancer Institute. Surveillance Epidemiology and End Results. Previous Version: SEER Cancer Statistics Review, 1975-2006. Available at http://seer.cancer.gov/csr/1975_2006, accessed November 20, 2010.
44. Romei C, Ciampi R, Faviana P et al. BRAFV600E mutation, but not RET/ PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 2008;15:511-520.
45. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009;69:8317-8325.
46. Liu D, Hu S, Hou P et al. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res 2007;13:1341-1349.
47. Ricarte-Filho JC, Ryder M, Chitale DA et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009;69:4885-4893.
48. Salvatore G, De Falco V, Salerno P et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623-1629.
49. Hoftijzer H, Heemstra KA, Morreau H et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Encorinol 2009;161:923-931.
50. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719.
51. Bentz BG, Miller BT, Holden JA et al. B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules. Otolaryngol Head Neck Surg 2009;140:709-714.
52. Cantara S, Capezzone M, Marchisotta S et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95:1365-1369.
53. Domingues R, Mendonça E, Sobrinho L et al. Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 2005;16:27-31.
54. Kim SK, Kim DL, Han HS et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008;17:118-125.
55. Marchetti I, Lessi F, Mazzanti CM et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid 2009;19:837-842.
56. Nam SY, Han BK, Ko EY et al. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: A potential guide for selection of samples for molecular analysis. Thyroid 2010;20:273-279.
57. Pizzolanti G, Russo L, Richiusa P et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid 2007;17:1109-1115.
58. Rowe LR, Bentz BG, Bentz JS. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006;3:10.
59. Salvatore G, Giannini R, Faviana P et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004;89:5175-5180.
60. Sapio MR, Guerra A, Posca D et al. Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer 2007;14:1089-1097.